Atlas of Experimental Gingivitis in Humans

University of North Carolina, Chapel Hill6 enrolled

Overview

Pilot case series with a split-mouth design to track subjects with known exposure (dental biofilm accumulation) over 21 days. Descriptive design, using single cell RNA sequencing as a "digital biopsy" to catalog and contrast inflamed versus non-inflamed tissues from within the same mouth and across patients. Specimens (human) will biobanked from the 'digital biopsy' site for future analysis, including: Gingival crevicular fluid, oral epithelial stem/progenitor cells, and plaque samples, for 'omics analyses including metabolomics, microbiomic, and genomic data.

Purpose is to conduct the first study of human gingiva in health and after biofilm-induced inflammation in the gingiva using scRNAseq. The pilot will involve induction of experimental gingivitis in all participants. Participants include recruitment of 6 participants. Following consenting, screening, and enrollment, a customized acrylic stent will be used only on the selected sextant/teeth specified in the protocol, and only during tooth brushing to prevent oral hygiene in selected sextant/teeth. After the completion of the 3-week gingivitis induction phase, participants will enter a 2 week resolution phase. In the resolution phase, participants will reinstate full mouth oral hygiene, with the exception of flossing. Oral prophylaxis will be performed to regain health. During the 3 week gingivitis induction phase, participants will be required to return to the clinic every 7 days for safety checks. Study Procedures (methods): Medical history, demographics (height/weight), urine based pregnancy test, vital signs (to include blood pressures, and pulse), standard dental clinical measures (to include plaque index, gingival index, bleeding on probing, and clinical attachment level), alginate impressions taken for fabrication of an acrylic stent (mouth guard), 2 gingival biopsies, 4 subgingival (below the gum line) plaque samples, 4 Gingival Crevicular Fluid (naturally occurring fluid between the gum and teeth) samples, and adult prophylaxis

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Gingivitis

Interventions

Stent-Induced Biofilm OvergrowthPROCEDURE

Customized acrylic dental (sextant) stent will be used during brushing for 21 days to influence reversible gingival tissue inflammation.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 30 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Adult males or females between the age of 18 and 30 years. * Non-diabetic and no history of smoking within the last 5 years. * Have read, understood and signed an informed consent form. * Must be able and willing to follow study procedures and instructions. * Must have at least 3 natural adjacent teeth in both maxillary (top) posterior sextants that will be selected for baseline gingival biopsy and SIBO gingival biopsy. * Must be in good general health, as evidenced by medical hx (exclusion conditions defined under subject exclusion criteria below). * Females of childbearing capacity must be willing to have pregnancy test to confirm they are not pregnant. Exclusion Criteria * History of intravenous bisphosphonates. * Current or history (less than 5 years) of tobacco use in any form prior to enrollment (self-report) * Chronic disease with oral manifestations including diabetes mellitus. * Infectious disease such as hepatitis, HIV, or tuberculosis. * Anemia or other blood dyscrasias. * Currently taking anticoagulant therapy or drugs, such as heparin or warfarin. * Those requiring antibiotic prophylaxis prior to dental treatment * Exhibiting gross oral pathology or a history of periodontal disease. * Individuals with a history or are currently using birth control containing hormones. * Individuals without a history (less than 1 year) of regular professional oral health care, including prophylaxis. (self-report) * Pregnant, breastfeeding or planning for pregnancy within 3 months. * Individuals who used antibiotics/chronically used NSAIDs * Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study.

Locations (1)

Adams School of Dentistry

Chapel Hill, North Carolina, United States

Outcomes

Primary Outcomes

Percent Composition of Human Gingival Tissue at Day 1

Percentage of the human gingival biopsies that are epithelial, immune, or mesenchymal cells in health.

Time frame: Day 1

Percent Composition of Human Gingival Tissue at Day 21

Percentage of the human gingival biopsies that are epithelial, immune, or mesenchymal cells during inflammation.

Time frame: Day 21

Percent Composition of Human Gingival Epithelial Cells at Day 1

Percentage of the human gingival epithelial cell subtypes that are present (i.e. keratinocytes, Langerhans cells, etc.) in health.

Time frame: Day 1

Percent Composition of Human Gingival Epithelial Cells at Day 21

Percentage of the human gingival epithelial cell subtypes that are present (i.e. keratinocytes, Langerhans cells, etc.) during inflammation.

Time frame: Day 21

Percent Composition of Human Gingival Immune Cells at Day 1

Percentage of the human immune cell subtypes that are present (i.e. CD4, CD8, etc.) in health.

Time frame: Day 1

Percent Composition of Human Gingival Immune Cells at Day 21

Percentage of the human immune cell subtypes that are present (i.e. CD4, CD8, etc.) during inflammation.

Time frame: Day 21

Percent Composition of Human Gingival Mesenchymal Cells at Day 1

Percentage of the human mesenchymal cell subtypes that are present (i.e. stromal endothelial, etc.) in health.

Time frame: Day 1

Percent Composition of Human Gingival Mesenchymal Cells at Day 21

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.